CRIS IL📊 Leads🔑 Keywords📋 Keyword Review📄 Papers🎤 Conference📬 Reports⚙ Config
D

Daniel Goldstein

Faculty of Medicine  ·  Tel Aviv University
H-index: 5  ·  Citations: 228  ·  Papers: 7
✉ not listed
View on CRIS ↗ ORCID ↗

Matched Keywords

electrocorticography
Deprioritized:cancercell

Research Areas (CRIS Fingerprint)

Cost-effectivenessMetastatic Colorectal Cancer (mCRC)NivolumabUnited StatesCost-effectiveness AnalysisImmune Checkpoint InhibitorsQuality-adjusted Life YearsChemotherapyOncologyNon-small Cell Lung Cancer (NSCLC)PembrolizumabCancer DrugsDrug CostsBevacizumabPharmacoeconomicsColorectal CancerOverall SurvivalTreatment DurationClinical TrialsLocally Advanced Non-small Cell Lung Cancer (LA-NSCLC)Advanced MelanomaProgrammed Death-ligand 1 (PD-L1)RadiotherapyAtezolizumabIncremental Cost-effectiveness RatioProgression-free SurvivalEconomic ImpactPositron Emission Tomography-computed Tomography (PET-CT)IpilimumabFixed DosingFinancial ImpactPharmacokinetic SimulationDrug ExpenditureTrastuzumabTreatment Strategy5-fluorouracil (5-FU)Next-generation SequencingTumorFractionation SchemeCancer CareImmuno-oncology AgentsPredictive MarkerPrecision MedicinePooled AnalysisAdvanced Renal Cell CarcinomaKaposi SarcomaHepatocellular CarcinomaIn SilicoPlanning MethodRegorafenibHealth Care CostMalignant NeoplasmOncologyCost-Effectiveness AnalysisNon Small Cell Lung CancerColorectal CarcinomaNivolumabOverall SurvivalMetastatic Colorectal CancerBevacizumabImmune Checkpoint InhibitorNeoplasmProgression Free SurvivalQuality Adjusted Life YearBreast CancerRadiation TherapyImmunotherapyPembrolizumabClinical TrialCancerProstate CancerNext Generation SequencingDiseasesTreatment DurationPancreas CancerPredictive MarkerPooled AnalysisPersonalized MedicineBladder CancerTreatment PlanningKaposi SarcomaSystematic ReviewMelanoma CellMerkel Cell CarcinomaRecurrent DiseaseAdjuvant ChemotherapyImmunoglobulinAdverse EventCohort AnalysisMelanomaMetastatic MelanomaCombination TherapyDiffuse Large B-Cell LymphomaPositron Emission Tomography-Computed TomographyTrastuzumabFinancial ToxicityFluorouracilEchocardiographyElectrocorticographyCancer TherapyMalignant NeoplasmChemotherapyMetastatic Colorectal CancerImmune Checkpoint InhibitorNivolumabNon Small Cell Lung CancerPharmacoeconomicsBevacizumabOverall SurvivalPembrolizumabColorectal CarcinomaPharmacokineticsAdverse EventClinical TrialMelanomaBreast CancerProgression Free SurvivalAtezolizumabFluorouracilDiseasesAnticancer DrugPancreas CancerLiver Cell CarcinomaRegorafenibCohort StudyMonoclonal AntibodyGemcitabineNeoplasmTrastuzumabTherapeutic Drug MonitoringRecurrent DiseaseIrinotecanRituximabIpilimumabBaseProstate CancerImmunotherapyKidney CancerFolinic AcidAnaplastic Lymphoma KinaseMerkel Cell CarcinomaArterial ThromboembolismNecitumumabCyclophosphamideDoxorubicinVincristineKaposi SarcomaPrednisoneColon CarcinomaSyndrome

Publications (36 linked — showing top 20)

Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum2026
Drug dose optimization and substitutions to improve access for patients with gastrointestinal and neuroendocrine cancers2025
Subcutaneous immunotherapy—a wolf in sheep's clothing?2025
Black Box Warning by the United States Food and Drug Administration: The Impact on the Dispensing Rate of Benzodiazepines2025
Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing2025
Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong2025
Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses2025
Adjuvant chemotherapy in T1a/bN0 breast cancer with a high 21-gene recurrence score (> 25): a 10-year follow-up in a real-world cohort2025
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring2025
Non-inferiority trials: tyranny or good governance? – Authors' reply2025
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC data2024
The tyranny of non-inferiority trials2024
Choosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancer2024
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending2024
“Choosing wisely” in oncology: The example of surveillance positron emission tomography-computed tomography (PET-CT) for patients with colorectal cancer (CRC) treated with curative intent.2024
Pragmatic solutions for optimizing oncology drug development trials2024
Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)2023
Corrigendum to “Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database” (European Journal of Cancer (2023) 178 (162–170), (S0959804922013259), (10.1016/j.ejca.2022.10.022))2023
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma2023
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies2023